Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP:BVAXF)

0.1660 -0.0033 (-1.95%)
Streaming Delayed Price Updated: 10:17 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,100
Open 0.1733
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1693
Today's Range 0.1590 - 0.1737
52wk Range 0.0148 - 0.2210
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2025 Corporate Review
Via TheNewswire.com
News headline image
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or... 
Via Newsfile

Performance

YTD
N/A
N/A
1 Month
+9.2%
+9.2%
3 Month
-23.2%
-23.2%
6 Month
+476.4%
+476.4%
1 Year
+255.5%
+255.5%

More News

Read More
News headline image
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
Via TheNewswire.com
Topics Intellectual Property
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
Via Investor Brand Network
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
Via FinancialNewsMedia
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Via FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
Via FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Via FinancialNewsMedia
Topics Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
Via FinancialNewsMedia
News headline image
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
Via FinancialNewsMedia
Topics Economy
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
Via FinancialNewsMedia
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE
Via FinancialNewsMedia
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Via FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
Via FinancialNewsMedia
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
Via FinancialNewsMedia
Topics Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
Via FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
Via FinancialNewsMedia
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Via FinancialNewsMedia
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
Via FinancialNewsMedia
Topics Intellectual Property

Frequently Asked Questions

Is Biovaxys Technology Corp publicly traded?
Yes, Biovaxys Technology Corp is publicly traded.
What exchange does Biovaxys Technology Corp trade on?
Biovaxys Technology Corp trades on the OTC Traded
What is the ticker symbol for Biovaxys Technology Corp?
The ticker symbol for Biovaxys Technology Corp is BVAXF on the OTC Traded
What is the current price of Biovaxys Technology Corp?
The current price of Biovaxys Technology Corp is 0.1660
When was Biovaxys Technology Corp last traded?
The last trade of Biovaxys Technology Corp was at 01/02/26 10:17 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.